ChemoCentryx Inc. (CCXI) is Trading Lower on Unusual Volume for January 21

Equities Staff |

ChemoCentryx Inc. (CCXI) experienced unusually high volume on Jan. 21, as the stock lost 1.95% to a closing price of $4.03. The stock saw 453,035 shares trade hands over the course of the day on 601 trades. Given that the stock’s average daily volume over the last month has been 162,867 shares a day, this represents a pretty substantial spike over the norm.

ChemoCentryx Inc. has a P/B ratio of 2.18. The stock has traded between $9.46 and $3.80 over the last 52-weeks, its 50-day SMA is now $6.75, and its 200-day SMA $7.26.

Chemocentryx Inc is a biopharmaceutical company engaged in discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer.

Headquartered in Mountain View, CA, ChemoCentryx Inc. has 58 employees and is currently under the leadership of CEO Thomas J. Schall.

For a complete fundamental analysis analysis of ChemoCentryx Inc., check out’s Stock Valuation Analysis report for CCXI. To see the latest independent stock recommendations from’s analysts, visit our Research section.


The Russell 3000 is not well known outside the world of finance, but it’s one of the strongest indices out there for getting a broad sense of the stock market. Unlike the better-known Dow Jones Industrial Average or S&P 500, membership on the Russell 3000 isn’t selected by committee. It’s simply the 3,000 most valuable companies in the country.

With 3,000 stocks making up the index, it gives a broad look at the markets, including the small-and mid-cap companies that aren’t on the Dow or the S&P 500. And with a rules-based system for determining membership, there’s no bias that could potentially limit membership. That’s why many financial professionals will turn to the Russell 3000 long before the better-known indices when trying to take the temperature of the market.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Inovio Pharmaceuticals Inc.

Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. The Company develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and…

Private Markets

Initial State

Initial State is an Internet of Things (IoT) data analytics & data management platform company. We turn sensor and event data into information that matters by making it easy to…


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.